Treating Oligometastatic Prostate Cancer in the PSMA PET Era
Andrew W. Hahn, MD, addresses the treatment of oligometastatic prostate cancer in the PSMA PET era from a medical oncology perspective.
Read More
Topic: Prostate Cancer
Updates on Global Screening Trials: Where Are We Headed Next?
R. Jonathan Henderson, MD, examines prostate cancer screening, emphasizing key trials and ongoing global efforts to improve detection.
Read More
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate Cancer
Steven J. Frank, MD, FACR, FABS, FASTRO, discusses advancements in MRI-assisted radiosurgery (MARS) for prostate cancer.
Read More
Transurethral Ultrasound Guided Prostate Ablation (TULSA): Clinical Trials and Real-world Results
Christian P. Pavlovich, MD, examines the use of TULSA in prostate cancer treatment, highlighting its technique, outcomes, and future potential.
Read More
Should Screening be Altered Based on Germline and Family History?
Sigrid V. Carlsson, MD, PhD, MPH, explores the role of genetics in risk-stratified prostate cancer screening.
Read More
Treating Neuroendocrine Prostate Cancer
William K. Oh, MD, explores neuroendocrine prostate cancer, emphasizing its increasing prevalence and aggressive nature.
Read More
Transperineal Prostate Biopsy in the Office Setting Anesthetic Considerations
Michael A. Gorin, MD, shares his transperineal prostate biopsy procedure under local anesthesia in the office setting.
Read More
Real-Time Intraoperative Neuromonitoring of Erectile and Urinary Functions During Radical Prostatectomy
Arthur L. Burnett II, MD, MBA, FACS, explores intraoperative neuromonitoring in radical prostatectomy.
Read More
Current Advances of Liquid Biopsies in Prostate Cancer
Edwin M. Posadas, MD, FACP, explores prostate cancer diagnostics and treatment, emphasizing biomarkers and liquid biopsy technologies.
Read More
Permanent Prostate Brachytherapy – Brian J. Moran Distinguished Lecture
Brian J. Davis, MD, PhD, discusses the complexities of focal brachytherapy versus whole gland treatment.
Read More
Managing Recurrence after Radical Prostatectomy
Adam S. Kibel, MD, explores managing prostate cancer recurrence following radical prostatectomy.
Read More
Role of Whole Gland Ablation in Prostate Cancer
James Wysock, MD, MS, delves into the evolving role of whole gland ablation (WGA) in prostate cancer management, particularly in intermediate- to high-risk cases and challenging clinical scenarios.
In this 20-minute presentation, Dr. Wysock highlights specific patient profiles where WGA may be preferable, including those with prior pelvic radiation, contraindications to surgery or radiotherapy, or elderly patients seeking less invasive yet effective treatment. In the salvage setting, WGA offers a compelling alternative for local recurrences, achieving substantial cancer control while avoiding aggressive surgical or radiation options.
Technological advancements like TULSA and HIFU enhance WGA precision. Challenges such as recurrence rates and in-field failures underscore the need for meticulous treatment planning and expanded ablation margins.
Dr. Wysock advocates for trials to validate WGA as a mainstream option, particularly in patients who cannot undergo radical treatments. This approach aligns with evolving guidelines and patient preferences, underscoring WGA’s potential as a transformative option in prostate cancer care.
Read More